Key Financial Figures - Standalone Performance

Income Statement (₹ Crores)

  • Revenue from operations: ₹2,119.24 (Q1 FY27) vs ₹1,746.90 (Q1 FY26) - 21% growth
  • Other income: ₹17.42 (Q1 FY27) vs ₹25.02 (Q1 FY26) - 30% decrease
  • Total income: ₹2,136.66 (Q1 FY27) vs ₹1,771.92 (Q1 FY26)

Expense Breakdown (₹ Crores)

  • Cost of materials consumed: ₹445.76
  • Purchases of stock-in-trade: ₹110.75
  • Changes in inventories: (₹16.10)
  • Employee benefits expense: ₹467.32
  • Finance costs: ₹5.04
  • Depreciation and amortization: ₹74.61
  • Other expenses: ₹533.87
  • Total expenses: ₹1,621.25

Profitability Metrics

  • Profit before exceptional items and tax: ₹515.41 (Q1 FY27) vs ₹356.75 (Q1 FY26)
  • Exceptional items: None in Q1 FY27 (₹30.42 crores in Q4 FY26 related to Labour Codes)
  • Profit before tax: ₹515.41
  • Tax expense: ₹142.12 (Current tax: ₹130.43, Short provision: (₹0.31), Deferred tax: ₹12.00)
  • Profit for the period: ₹373.29 (Q1 FY27) vs ₹262.04 (Q1 FY26) - 42% growth
  • Earnings per share (₹): Basic/Diluted: 14.71 (Q1 FY27) vs 10.33 (Q1 FY26)

Other Financial Data

  • Paid-up equity share capital: ₹25.37 crores (face value ₹1 each)
  • EBITDA before forex gain/loss and other income: ₹556.82 crores, up 34% YoY
  • Forex gain: (₹20.82) crores

Key Financial Figures - Consolidated Performance

Income Statement (₹ Crores)

  • Revenue from operations: ₹2,788.10 (Q1 FY27) vs ₹2,308.85 (Q1 FY26) - 21% growth
  • Other income: ₹25.26 (Q1 FY27) vs ₹32.66 (Q1 FY26)
  • Total income: ₹2,813.36

Profitability Metrics

  • Profit before exceptional items & tax: ₹572.08
  • Exceptional items: None in Q1 FY27 (₹45.82 crores in Q4 FY26)
  • Profit before tax: ₹572.08
  • Tax expense: ₹149.27
  • Profit for the period before share of associates: ₹422.81, up 80% YoY
  • Net profit attributable to owners: ₹401.89, up 72% YoY
  • Earnings per share (₹): Basic/Diluted: 15.84 (Q1 FY27) vs 9.19 (Q1 FY26)

Revenue Breakdown (₹ Crores)

Standalone Revenue Composition

  • Formulations - Domestic: ₹1,082.12 (13% growth)
  • Formulations - Exports: ₹603.04 (Branded: ₹143.27, Institutional: ₹119.75, Generics: ₹340.02)
  • APIs - Domestic: ₹91.37
  • APIs - Exports: ₹332.35
  • Other operating income: ₹10.36

Consolidated Revenue

  • Subsidiaries revenue: ₹668.86
  • Total consolidated revenue: ₹2,788.10

Geographic Revenue Distribution (Consolidated)

  • India: ₹1,558.89
  • Outside India: ₹1,229.21

Exceptional Items Disclosure

Previous Year Exceptional Items (FY26)

  • Impact of new Labour Codes: ₹30.42 crores (standalone), ₹45.82 crores (consolidated) - Resulting from enactment of four Labour Codes on November 21, 2025, which increased gratuity and leave liability
  • Interest settlement of European Commission: ₹58.26 crores (consolidated) - Settlement of fine and interest by Unichem Laboratories
  • Net gain on disposal of land & building: (₹17.65) crores (consolidated) - Gain from sale of property by Unichem Laboratories

Corporate Development

  • The Board resolved on June 26, 2026, to amalgamate Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary approvals
  • Appointed date for amalgamation: April 1, 2026
  • No effect given to this amalgamation in the current financial results pending approvals

Audit and Compliance

  • Statutory Auditors N V C & Associates LLP conducted limited review and issued unmodified reports
  • Financial results prepared in accordance with Indian Accounting Standards (IND-AS)
  • Figures for quarter ended March 31, 2026, are balancing figures between audited annual figures and previously published unaudited figures

Operational Segments

  • The Company has only one operating segment: Pharmaceuticals
  • Geographic information shows non-current assets outside India are less than 10% of total non-current assets